Clinical Collaborations

PTSD, Social Anxiety Disorder (SAD), Pain

NYU Grossman School of Medicine, NYU

New York, USA


Clinical studies at the NYU Grossman school of Medicine are evaluating our investigational drug Nantheia™A1002 for PTSD (Principal Investigators: Charles Marmar MD, and Esther Blessings MD., Ph.D), and Radiculopathic Pain (Prinicpal Investigator: Stephen Ross, MD), and evaluating our investigational drug Nantheia™ ATL5 for Social Anxiety Disorder (Principal Investigators: Naomi Simon MD, M.Sc., and Esther Blessing MD, Ph.D.)


Opioid Use Disorder (OUD)

Geffen School of Medicine, UCLA

Los Angeles, CA, USA


A clinical study at the Geffen School of Medicine, UCLA, is evaluating the safety and tolerability of Nantheia™ ATL5 for Opioid Use Disorder (Principal Investigators: Edythe London, Ph.D. Additionally, this study seeks to ascertain the efficacy of Nantheia™ATL5 in mitigating opioid cravings.

Opioid Use Disorder

Icahn School of Medicine, Mt Sinai, NYC

New York, USA


Mt. Sinai have recently completed a phase 1 trial evaluating the Pharmacokinetic Profile of Nantheia™ ATL5 versus Epidiolex™. Results from this study will be published in the near future.



University of Nebraska Medical Center

Omaha, Nebraska, USA


At the University of Nebraska Medical Center, a clinical trial is underway to evaluate Nantheia™ ATL5 for PTSD (Principal Investigator: Mathew Rizzo, MD, FAAN,FANA.) This is our second PTSD study focused on PTSD.


University of Florida

Tampa Bay, FL, USA


At the University of Florida, we are undertaking additional preclinical studies (Principal Investigator: Mark Kindy Ph.D.,) with our proprietary Liquid Structure™ cannabinoid formulations to further our understanding of the mode of action of our proprietary formulations in the body.


Phase I Study and Preclinical Study

Hadassah Hospital

Jerusalem, Israel


Hadassah Hospital completed a Phase 1 trial, assessing the bioavailability and safety of of our Liquid Structure™ cannabidiol formulations, versus CBD in Olive Oil, in 2020 (Principal Investigator; Professor Caraco MD.) Recently we have completed additional preclinical studies at Haddassah (Principal Investigator Osmat Hazan Ph.D) exploring modes of action for our Liquid Structure ™ formulations.

Grounded in Science, driven by innovation, we strive to make a meaningful impact on global healthcare